Peptide G

Drug Profile

Peptide G

Alternative Names: Antagonist G; PTL 68001; PTL 68300B

Latest Information Update: 30 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cancer Research Technology
  • Class Antineoplastics
  • Mechanism of Action Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 21 Feb 2002 A phase I study has been added to the Cancer pharmacokinetics and adverse events sections
  • 30 Oct 2000 A phase I study has been added to the Cancer adverse events section
  • 06 Oct 1998 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top